{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:25:05Z","timestamp":1793193905357,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hereditary hemorrhagic telangiectasia (HHT) results in recurrent severe epistaxis, chronic gastrointestinal bleeding, and other morbid manifestations. Pomalidomide was recently demonstrated to be efficacious for bleeding in HHT in the landmark PATH-HHT trial. Given that the vascular remodeling that results in bleeding improvement may require several months, characteristics associated with treatment response would be invaluable to plan treatment. Using data from PATH-HHT (NCT03910244), we identified characteristics associated with change from baseline in Epistaxis Severity Score (ESS; a well-validated 10-point HHT bleeding scale and the trial\u2019s primary end point) using multivariable-adjusted repeated-measures models. Characteristics associated with a better response to pomalidomide at weeks 16 to 24 of the trial included a higher (more severe) baseline ESS (change from baseline, \u22120.76 [95% confidence interval (CI), \u22120.99 to \u22120.54] points per 1-point higher baseline score, P&amp;lt; .001) and concomitant antifibrinolytic therapy (\u22120.73 [95% CI, \u22121.48 to 0.01] vs no therapy, P = .05). Characteristics associated with a less robust response were older age (0.29 [95% CI, 0.05-0.53] per 10 years older, P = .02) and underlying ACVRL1 germ line mutation (0.62 [95% CI, \u22120.04 to 1.27] vs ENG, SMAD4, or mutation not known, P = .06]. Characteristics notably associated with placebo response (placebo effect) were patient-reported outcome measures, such that those experiencing more severe disease at baseline had less placebo effect. In conclusion, several baseline patient and disease characteristics were associated with pomalidomide response, findings that may help guide patient selection for the use of pomalidomide in HHT. This trial was registered at www.Clinicaltrials.gov as NCT03910244.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019484","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:07:26Z","timestamp":1771618046000},"page":"2967-2976","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics associated with clinical response to pomalidomide in hereditary hemorrhagic telangiectasia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[{"name":"1Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-5627","authenticated-orcid":false,"given":"Sonia M.","family":"Thomas","sequence":"additional","affiliation":[{"name":"2RTI International, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-9290","authenticated-orcid":false,"given":"Derek","family":"Marsh","sequence":"additional","affiliation":[{"name":"2RTI International, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-3082","authenticated-orcid":false,"given":"Raj S.","family":"Kasthuri","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-9319","authenticated-orcid":false,"given":"Vivek N.","family":"Iyer","sequence":"additional","affiliation":[{"name":"4Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson M.","family":"Pishko","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3440-9682","authenticated-orcid":false,"given":"Jake E.","family":"Decker","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2180-1731","authenticated-orcid":false,"given":"Clifford R.","family":"Weiss","sequence":"additional","affiliation":[{"name":"7Department of Radiology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0419-7309","authenticated-orcid":false,"given":"Kevin J.","family":"Whitehead","sequence":"additional","affiliation":[{"name":"8Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7583-0493","authenticated-orcid":false,"given":"Miles B.","family":"Conrad","sequence":"additional","affiliation":[{"name":"9Department of Radiology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9552-475X","authenticated-orcid":false,"given":"Marc S.","family":"Zumberg","sequence":"additional","affiliation":[{"name":"10Division of Hematology\/Oncology, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-4946","authenticated-orcid":false,"given":"Jenny Y.","family":"Zhou","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Parambil","sequence":"additional","affiliation":[{"name":"14Division of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-2232","authenticated-orcid":false,"given":"Benjamin","family":"Carper","sequence":"additional","affiliation":[{"name":"2RTI International, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Clancy","sequence":"additional","affiliation":[{"name":"13CureHHT, Monkton, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-475X","authenticated-orcid":false,"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[{"name":"12Division of Hematology\/Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"1","key":"2026050815185898300_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2796.1999.00398.x","article-title":"Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients","volume":"245","author":"Kjeldsen","year":"1999","journal-title":"J Intern Med"},{"issue":"1","key":"2026050815185898300_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1017\/cjn.2018.360","article-title":"Links between strokes and hereditary hemorrhagic telangiectasia: a population-based study","volume":"46","author":"Chowdhury","year":"2019","journal-title":"Can J Neurol Sci"},{"issue":"12","key":"2026050815185898300_bib3","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/bloodadvances.2023011961","article-title":"Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder in women","volume":"8","author":"Zhang","year":"2024","journal-title":"Blood Adv"},{"key":"2026050815185898300_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2017.03.003","article-title":"Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: a cross-sectional survey","volume":"153","author":"Chaturvedi","year":"2017","journal-title":"Thromb Res"},{"issue":"1","key":"2026050815185898300_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jtha.2025.09.024","article-title":"Validation and clinical application of the hereditary hemorrhagic telangiectasia-specific quality of life scale","volume":"24","author":"Al-Samkari","year":"2026","journal-title":"J Thromb Haemost"},{"key":"2026050815185898300_bib6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24832","article-title":"Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia","author":"Kasthuri","year":"22  2017","journal-title":"Am J Hematol"},{"issue":"2","key":"2026050815185898300_bib7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1572-0241.2000.01792.x","article-title":"Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia","volume":"95","author":"Kjeldsen","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"18","key":"2026050815185898300_bib8","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.0000000000001538","article-title":"Complications and mortality in hereditary hemorrhagic telangiectasia: a population-based study","volume":"84","author":"Donaldson","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"2026050815185898300_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13023-020-01579-2","article-title":"Predictors of mortality in patients with hereditary hemorrhagic telangiectasia","volume":"16","author":"Thompson","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2026050815185898300_bib10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective","volume":"103","author":"Kritharis","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"2026050815185898300_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"issue":"7","key":"2026050815185898300_bib12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.2020008739","article-title":"Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care","volume":"137","author":"Al-Samkari","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2026050815185898300_bib13","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"2026050815185898300_bib14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2312749","article-title":"Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia","volume":"391","author":"Al-Samkari","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2026050815185898300_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"issue":"9","key":"2026050815185898300_bib16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood.2023021765","article-title":"How I treat bleeding in hereditary hemorrhagic telangiectasia","volume":"144","author":"Al-Samkari","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026050815185898300_bib17","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3026(21)00164-2","article-title":"Giving hereditary haemorrhagic telangiectasia the attention it deserves","volume":"8","author":"Al-Samkari","year":"2021","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026050815185898300_bib18","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2025018382","article-title":"Pomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS)","volume":"10","author":"Zhang","year":"2026","journal-title":"Blood Adv"},{"issue":"5","key":"2026050815185898300_bib19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lary.25669","article-title":"The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia","volume":"126","author":"Yin","year":"2016","journal-title":"Laryngoscope"},{"issue":"10","key":"2026050815185898300_bib20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ajh.70011","article-title":"Standardization of terminology, definitions, and outcome criteria for bleeding in hereditary hemorrhagic telangiectasia: international consensus report","volume":"100","author":"Al-Samkari","year":"2025","journal-title":"Am J Hematol"},{"issue":"11","key":"2026050815185898300_bib21","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study","volume":"2","author":"Invernizzi","year":"2015","journal-title":"Lancet Haematol"},{"issue":"11","key":"2026050815185898300_bib22","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1182\/bloodadvances.2024012589","article-title":"Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia","volume":"8","author":"Wang","year":"2024","journal-title":"Blood Adv"},{"issue":"10","key":"2026050815185898300_bib23","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/ajh.27756","article-title":"Characterizing the healthcare utilization and costs of hereditary hemorrhagic telangiectasia","volume":"100","author":"Al-Samkari","year":"2025","journal-title":"Am J Hematol"},{"issue":"5","key":"2026050815185898300_bib24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0042-1743467","article-title":"Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians","volume":"48","author":"Al-Samkari","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2026050815185898300_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jtha.2022.09.003","article-title":"Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia","volume":"21","author":"Virk","year":"2023","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2967\/2515750\/blooda_adv-2025-019484-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2967\/2515750\/blooda_adv-2025-019484-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:19:07Z","timestamp":1778267947000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/2967\/566677\/Characteristics-associated-with-clinical-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019484","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,4,29]]}}}